Abstract:Abstract Background: Pts with mCSPC receiving ADTi and achieving PSA nadir ≤0.2 ng/mL (PSA-L) have better overall survival (OS) compared to those with a PSA nadir > 0.2 ng/mL (PSA-H). We investigate differences in genomic and transcriptomic profiling between PSA-L and PSA-H. Methods: In this IRB-approved retrospective study, eligibility criteria included confirmed mCSPC receiving ADTi and having comprehensive genomic profiling (CGP) performed by a CLIA-certified lab (Foundation Medicine and Tempus). Transcriptomic profile was evaluated from Tempus cohort. Pts were divided into 2 groups: PSA-L and PSA-H based on achieving a PSA nadir ≤0.2 ng/mL at any time during treatment course. The DEseq2 pipeline was used to analyze differentially expressed genes between the groups. The data included the Log2 fold change, Wald-Test p-values, and Benjamini-Hochberg adjusted p values (q values) for each differentially expressed gene. These results were subjected to Gene Set Enrichment Analysis (GSEA) to identify pathways enriched in each cohort. All bioinformatic analysis was undertaken using R studio v4.2. Results: 248 pts were eligible for genomic analysis (PSA-L=166, PSA-H=82). The top 5 most commonly altered genes were TMPRSS2, TP53, PTEN, APC, and SPOP. Genomic analysis did not reveal significant differences between PSA-L and PSA-H. 78 pts were eligible for transcriptomic analysis (PSA-L=55, PSA-H=23). Table shows differences in the expression of pathways between PSA-L and PSA-H. Conclusion: While there were no significant differences in genomic aberrations between PSA-L and PSA-H, gene expression profiling showed significant variations in crucial pathways, particularly the AR pathway, which might explain the better outcomes in PSA-L. After external validation, these findings may help personalize medicine prior to initiation of therapy. Differential gene set expression scores in PSA-L vs. PSA-H Pathway Normalized Enrichment Score (NES)* p-value q-value TNF-α signaling via NFKB 2.5 <0.01 <0.01 Androgen Response 1.7 <0.01 <0.01 Estrogen Response 1.7 <0.01 <0.01 Interferon-α 1.5 <0.01 <0.01 Bile Acid Metabolism -1.5 <0.01 <0.01 Coagulation -1.7 <0.01 <0.01 Epithelial Mesenchymal Transition -1.9 <0.01 <0.01 Citation Format: Vinay Mathew Thomas, Beverly Chigarira, Georges Gebrael, Chadi Chehade, Arshit Narang, Nicolas Sayegh, Nishita Tripathi, Yeonjung Jo, Clara Tandar, Ayana Srivastava, Richard Ji, Emre Dal, Gliceida Galarza Fortuna, Haoran Li, Benjamin L. Maughan, Umang Swami, Neeraj Agarwal. Tumor genomic and transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus do not achieve an optimal PSA response to androgen deprivation therapy intensification (ADTi) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1136.

Dissecting the Significance of Acid Phosphatase 1 Gene Alterations in Prostate Cancer

Molecular Characterization of Clinically Defined Aggressive Variant Prostate Cancer (avpca) in Prospectively Collected Tissues and Corresponding Patient Derived Xenografts (PDX).

AVPC Molecular Signature Supplementary Figures from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

Targeting prostate tumor low–molecular weight tyrosine phosphatase for oxidation-sensitizing therapy

Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes

Abstract C108: ANPEP regulates one-carbon metabolism in prostate cancer

Association of transcriptomic biomarkers with adverse pathologic features at radical prostatectomy among active surveillance eligible men.

Diagnostic role and prognostic impact of PSAP immunohistochemistry: A tissue microarray study on 31,358 cancer tissues from 127 different tumor types

Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues

Albumin-to-alkaline Phosphatase Ratio Serves As a Prognostic Indicator in Unresectable Pancreatic Ductal Adenocarcinoma: a Propensity Score Matching Analysis

Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.

PCAT-1 Expression is Associated with the Prognosis in Prostate Cancer.

Global Proteomics Analysis of Lysophosphatidic Acid Signaling in PC-3 Human Prostate Cancer Cells: Role of CCN1

Insights into autotaxin- and lysophosphatidate-mediated signaling in the pancreatic ductal adenocarcinoma tumor microenvironment: a survey of pathway gene expression

Immune Infiltrates and PD-L1 Expression in Treatment-Naïve Acinar Prostatic Adenocarcinoma: an Exploratory Analysis

The opposing effects of Class 1B and Class 2 FOXA1 mutations in prostate cancer.

Abstract 773: Overexpression of phosphoserine phosphatase (PSPH) in prostate cancer and in tumor microenvironment promotes tumor cell proliferation

Abstract 1136: Tumor genomic and transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus do not achieve an optimal PSA response to androgen deprivation therapy intensification (ADTi)

Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.

Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status

ACYP1 Is a Pancancer Prognostic Indicator and Affects the Immune Microenvironment in LIHC